Our Investment in the Future of GI
Phathom is proud to support a broad range of programs that offer support and resources to researchers, healthcare providers, patients and their advocates, as well as our local communities.
Phathom will consider funding initiatives for programs based in the United States in the general therapeutic area of acid-related gastrointestinal disorders, where our current area of focus is symptomatic Gastroesophageal Reflux Disease (GERD) and our target audience is GI- focused healthcare providers.